1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Epizyme Appoints CEO

 
• By Lucie Ellis-Taitt

Epizyme, Inc., a clinical stage biopharmaceutical R&D company creating epigenetic therapeutics for cancer patients, has named Robert Bazemore president and CEO, effective Sept. 10, 2015. Bazemore will also join the Epizyme board of directors. He succeeds Dr Robert Gould who has served on the Epizyme board of directors since 2008 and as CEO for the past five-and-a-half years. Following the transition, Gould will continue to serve on the board and as a consultant to the company.

Epizyme, Inc., a clinical stage biopharmaceutical R&D company creating epigenetic therapeutics for cancer patients, has named Robert Bazemore president and CEO, effective Sept. 10, 2015. Bazemore will also join the Epizyme board of directors. He succeeds Dr Robert Gould who has served on the Epizyme board of directors since 2008 and as CEO for the past five-and-a-half years. Following the transition, Gould will continue to serve on the board and as a consultant to the company.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

Astellas Gets CLDN.18.2-Targeted ADC From China’s Evopoint

 
• By Joseph Haas

Astellas will pay $130m up front for near-global rights to a Phase I/II antibody-drug conjugate that will add to its portfolio of CLDN.18.2-targeted drugs, including Vyloy.

Merck & Co./Daiichi Pull Patritumab Deruxtecan BLA On Disappointing OS

 
• By Jessica Merrill

Patritumab deruxtecan is the lead antibody drug conjugate in a $22bn deal signed between the two partners, with the decision marking a disappointing setback

Senti’s Computer-Logic Inspired Cell Therapy Shows Early Promise

 
• By Andrew McConaghie

The biotech believes its logic-gated cell therapies can get round the need for ‘clean targets’ which limit CAR-Ts and ADCs.

All Over For iTeos But Applause For Plan To Return Cash Fast

 
• By Kevin Grogan

The company has moved quickly to wind down operations after its anti-TIGIT pact with GSK collapsed.

More from Therapy Areas

Senti’s Computer-Logic Inspired Cell Therapy Shows Early Promise

 
• By Andrew McConaghie

The biotech believes its logic-gated cell therapies can get round the need for ‘clean targets’ which limit CAR-Ts and ADCs.

All Over For iTeos But Applause For Plan To Return Cash Fast

 
• By Kevin Grogan

The company has moved quickly to wind down operations after its anti-TIGIT pact with GSK collapsed.

In Brief: Nicox Extends Cash Runway As Kowa Advances NCX 470 In Japan

 
• By Sushmita Panda

Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.